Types segmentation classifies the technological foundations underpinning Monogenic Disease Testing. DNA sequencing methods, including targeted next‑generation sequencing (NGS) panels, whole‑exome sequencing (WES), and whole‑genome sequencing (WGS), dominate the market due to their comprehensive variant detection, contributing the largest share of test volume. Polymerase chain reaction (PCR)‑based assays—such as allele‑specific PCR and quantitative PCR—retain relevance for single‑gene, high‑throughput screens, especially in carrier and prenatal contexts, representing a modest but steady revenue stream. Microarray platforms, while declining, still serve population‑scale carrier screening where known single‑nucleotide polymorphisms are interrogated en masse. Emerging CRISPR‑based diagnostics offer rapid, point‑of‑care detection of specific monogenic mutations, currently a niche segment with high growth potential. Each type aligns with particular clinical workflows and cost structures, collectively defining the market taxonomy and influencing investment allocation across development, manufacturing, and distribution channels.